This was published under the 2010 to 2015 Conservative and Liberal Democrat coalition government
New review explores the catalytic role of PDPs as countries decide whether to adopt new products
When a new health product becomes available, countries have a choice to adopt the product into their national health systems or to pursue an alternate strategy to address the public health problem. Product Development Partnerships (PDPs) often provide inputs into international policy setting – but what role do PDPs play in national-level decisions over product adoption?
The findings of a new review co-written by the TB Alliance’s Director of Market Access, Dr. William Wells, along with the PATH Malaria Vaccine Initiative’s former Director of Policy and Access, Alan Brooks, suggest that PDPs can and do play a catalytic role as countries consider whether to adopt new products.
Countries drive the decision-making process. Inputs from multiple stakeholders can reduce otherwise lengthy delays in availability, and PDPs can contribute based on their familiarity with the evidence base that assists decision making. The strategy for engaging in these decision-making processes will vary by disease and intervention area. Activities, as described in the review, include country consultations, regional meetings or committees, development of decision-making frameworks, provision of technical assistance, and conduct of Phase 4 studies. To reach large numbers of countries, the formation of partnerships, particularly with the World Health Organization, are essential.
Read the review Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making, published in the journal Health Research Policy and Systems.
Click here for more information on PDPs supported by DFID, including the